NDATOPICALGELPriority Review
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILSUVEZ is a topical gel containing birch triterpenes approved by the FDA in December 2023 for the treatment of epidermolysis bullosa simplex, a rare genetic blistering disorder. The mechanism of action is not fully characterized in available data, but birch triterpenes are believed to support wound healing and skin integrity. This is a first-in-class botanical therapeutic for a serious rare disease with limited treatment options.
Growth12.7 years to LOE
Early-stage launch phase with no established competitors creates opportunity for rapid market development and team expansion in commercial and medical affairs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Started Dec 2024
580 enrolled
Epidermolysis Bullosa, DystrophicEpidermolysis Bullosa, Junctional
Career Relevance
FILSUVEZ represents a rare opportunity to build a commercial franchise from launch in an uncontested market with 12+ years of patent protection. Professionals joining this product now can shape market development strategy, payer relationships, and patient access programs with minimal competitive distraction and significant upside potential.
Brand Manager
Worked on FILSUVEZ at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.